Oakwood Medical Investors III

Portfolio Companies

 

Achillion Pharmaceuticals, Inc. (NasdaqGM: ACHN) is a product-focused pharmaceutical company dedicated to the discovery and development of innovative therapeutic agents, with a particular emphasis on antiviral drugs to treat infections caused by human immunodeficiency virus (HIV), hepatitis and resistant bacterial infections.

 

Adiana, Inc. (acquired by Cytyc Corporation) was founded to develop and market novel technologies for non-surgical, office-based gynecological procedures. Adiana has developed a technology for permanent female sterilization via fallopian tube occlusion that can be performed non-surgically in a physician's office.

 

Argos Therapeutics, Inc. is an immunotherapy company developing novel cancer vaccines containing potent immunostimulating dendritic cells loaded with mRNA from the patient's tumor. Argos is currently utilizing this technology to develop therapeutics for metastatic renal cell carcinoma, melanoma, chronic lymphocytic leukemia, lupus and HIV.      

Broncus Technologies is developing Interventional Bronchoscopy devices to address the unmet needs of people with emphysema.

CardioNow, Inc. (acquired by Heartlab, Inc.) provides outsourced storage of digital imaging and communications (DICOM) for the cardiology community. With CardioNow's technology, cardiac images and data are instantly available over the Internet for viewing, analyzing and sharing, anywhere and anytime, without ever compromising patient or organizational confidentiality.

CryoCor, Inc. (NasdaqNM: CRYO) is creating new cryoablation techniques to treat atrial fibrillation and other arrhythmias. The Company's lead product is the CryoCor™ Cardiac Cryoablation System. This device treats atrial fibrillation (abnormal heart rhythm) by creating electrically isolating lesions within the heart using cold energy.

Insulet Corporation (NasdaqGM: PODD) is developing revolutionary disposable products for the treatment of insulin-dependent diabetes. The company's initial product will be a disposable insulin pump designed to compete as the technologically superior, cost-efficient leader in the growing market of subcutaneous insulin infusion.

 

OptiScan Biomedical Corporation is a development stage company with a proprietary method of measuring blood glucose using an optical approach. OptiScan intends to create the next generation of blood glucose meters that will deliver a new standard of clinically relevant accuracy.

POINT Biomedical Corporation is a development stage pharmaceutical company focusing on novel technologies for the delivery of diagnostic and therapeutic agents. POINT Biomedical has developed acoustically responsive microspheres using proprietary pharmaceutical and biomaterial technologies. This platform addresses two large market opportunities: myocardial perfusion imaging for the diagnosis and evaluation of therapy in coronary heart disease, and ultrasonically triggered drug delivery.

Quick Study Radiology, Inc. provides information technology management services for hospital radiology departments. In particular, the company provides implementation and support of an integrated digital radiology information system, including picture archive communication systems (PACs), radiology information systems (RIS), archiving, web distribution and interfaces. QSR's client list includes community hospitals, imaging centers and physician groups in four states.

TransMolecular, Inc. is committed to discovering, developing and commercializing novel and proprietary drugs to diagnose and treat challenging diseases where there are inadequate pharmaceutical alternatives. The Company's lead product is a novel targeted anti-cancer therapeutic and imaging agent to treat adult recurrent glioma (brain tumors).